JOIN US — MAKE YOUR MARK
To learn more about careers with goetzpartners, visit our careers website at:www.joingoetzpartners.com
Vicore Pharma Holding AB (Nasdaq First North: VICO) announced that the EGM on 7 January 2019 approved the board of directors’ resolution on a directed issue of 9,414,706 new shares at a subscription price of SEK 17 per share from 30 November 2018. The issue raised proceeds of around SEK 160 million before issue costs from a number of selected Swedish and international long-term institutional investors and sector specialist funds, including HealthCap, Nordic Cross, Fjärde AP-fonden, Handelsbanken Fonder, HBM Healthcare Investments, Alfred Berg, Swedbank Robur, Eriksam Invest Aktiebolag and Unionen. The subscription price had been determined through a book building procedure and represents a discount of 4.3 per cent compared to volume weighted average for the Vicore Pharma share during the last five trading days up to and including 29 November 2018. The proceeds are expected to further the development of Vicore's drug development programs VP01 and VP02. The company plans (i) for a 3-months phase II proof of concept study in idiopathic pulmonary fibrosis ("IPF") with lung function and safety as endpoints, (ii) the development of a commercial formulation of C21 and a pilot study for C21 in a second indication, (iii) to generate clinical data for its second program, VP02, for patients with severe IPF.
goetzpartners securities Limited acted as joint financial adviser in the directed share issue.
ABOUT VICORE PHARMA
Vicore Pharma is a Swedish rare disease company focused on interstitial lung diseases and related indications. The Company currently has two drug development programs, VP01 and VP02. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis IPF. As a result of the acquisition of INIM Pharma AB in August 2018, the Company’s pipeline was expanded with a second drug development program, VP02. Based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”), VP02 focuses on IPF with regards to both the underlying disease and the severe cough associated with IPF.
Martin Brunninger Managing Director Email
Wolf Dornbusch Director
Youchen Xin Associate
Erland Sternby Marketing Sales